Intravenous Dexmedetomidine for Cesarean Section

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 7, 2017

Primary Completion Date

September 30, 2017

Study Completion Date

October 5, 2017

Conditions
Breast FeedingAnalgesia ObstetricalPostoperative Pain
Interventions
DRUG

Normal Saline

Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.

DRUG

Dexmedetomidine 0.03ug/kg/h

Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.

DRUG

Dexmedetomidine 0.05ug/kg/h

Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.

DRUG

Dexmedetomidine 0.08ug/kg/h

Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.

Trial Locations (1)

210029

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT03065530 - Intravenous Dexmedetomidine for Cesarean Section | Biotech Hunter | Biotech Hunter